MCT4 is an independent prognostic factor and affects immune cell infiltration in patients with colorectal liver oligometastases
Clinical and Translational Oncology · 13.09.2024 · 27 (4) · 1681-1694
DOI: 10.1007/s12094-024-03720-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Oncology, online erschienen am 13.09.2024. Verfasst von Jiahua He und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Colorectal Surgery, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinica…. Hauptthemen laut MEDLINE: Monocarboxylic Acid Transporters, Colorectal Neoplasms, Liver Neoplasms, Lymphocytes, Tumor-Infiltrating. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Natural Science Foundation of Guangdong Province, Shenzhen Science and Technology Innovation Program, Beijing Xisike Clinical Oncology Research Foundation.
Abstract (Originalsprache)
BACKGROUND: Monocarboxylate transporter 4 (MCT4) is a novel biomarker related to the level of immune cell infiltration, but its impact on tumor immune microenvironment (TIME) of colorectal liver oligometastases (CLO) remains unclear. The aim of this study was to assess MCT4 expression in primary tumor and liver oligometastases, investigate its impact on immune cell infiltration and its prognostic value for CLO patients undergoing liver resection. METHODS: We retrospectively selected 135 CLO patients who underwent curative liver resection between June 1999 and December 2016, and samples included 74 primary tumor tissues and 122 liver metastases. Immunohistochemistry (IHC) was performed to detect MCT4 expression in paraffin-embedded specimens and tyramine signal amplification (TSA) was used to detect the density of tumor-infiltrating lymphocytes, including CD3 + , CD8 + and Foxp3 + . Recurrence-free survival (RFS) and overall survival (OS) were analyzed using the Kaplan-Meier method and log-rank test, and independent prognostic factors were identified with Cox regression modeling. RESULTS: Survival analysis indicated that CLO patients with low MCT4 expression had better 3-year RFS and 3-year OS rates than those with high MCT4 expression. Multivariate analysis indicated that high MCT4 expression was independently associated with poor RFS and OS. High MCT4 expression was associated with a lower number of intratumoral CD3 + /CD8 + T cells and was associated with higher Foxp3 + T cells infiltration. Patients with low MCT4 expression and high levels of differential immune infiltration had longer survival. CONCLUSIONS: MCT4 overexpression was associated with an unfavorable prognosis in patients with CLO and MCT4 expression level had an impact on intratumoral immune infiltration degree. A novel parameter that combined MCT4 expression level and differential immune infiltration level was constructed to stratify patients with CLO into different risk groups.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Colorectal Surgery, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, Guangdong, People's Republic…
- Department of Pathology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, People's Republic of China.
- Department of Gastroenterology, Peking University Shenzhen Hospital, Shenzhen, Guangdong, People's Republic of China.
- Medical College, Shaoguan University, Shaoguan, Guangdong, People's Republic of China.
- Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China. xingy28@mail.sysu.edu.cn.
- Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China. xingy28@mail.sysu.edu.cn.
Förderung
- Natural Science Foundation of Guangdong Province
- Shenzhen Science and Technology Innovation Program
- Beijing Xisike Clinical Oncology Research Foundation
Zitieren
APA
He, J., Li, W., Wang, J., Wu, X., Zhang, W., Lin, J., Xiao, B., Yu, L., Liao, L., Wang, S., Wang, W., Lin, Y., Hong, X., Xing, Y., Pan, Z., & Peng, J. (2024). MCT4 is an independent prognostic factor and affects immune cell infiltration in patients with colorectal liver oligometastases. Clinical and Translational Oncology, 27(4), 1681-1694. https://doi.org/10.1007/s12094-024-03720-0
Vancouver
He J, Li W, Wang J, Wu X, Zhang W, Lin J, et al. MCT4 is an independent prognostic factor and affects immune cell infiltration in patients with colorectal liver oligometastases. Clinical and Translational Oncology. 2024;27(4):1681-1694. doi:10.1007/s12094-024-03720-0
BibTeX
@article{He2024,
author = {He, Jiahua and Li, Weihao and Wang, Jiayu and Wu, Xiaojun and Zhang, Weili and Lin, Junzhong and Xiao, Binyi and Yu, Long and Liao, Leen and Wang, Song and Wang, Weifeng and Lin, Yuguang and Hong, Xuanlin and Xing, Yue and Pan, Zhizhong and Peng, Jianhong},
title = {MCT4 is an independent prognostic factor and affects immune cell infiltration in patients with colorectal liver oligometastases},
journal = {Clinical and Translational Oncology},
year = {2024},
volume = {27},
number = {4},
pages = {1681--1694},
doi = {10.1007/s12094-024-03720-0}
}
EUVIMED